Neeraj Mishra – författare

Emerging Paradigms in Delivery Systems for Antitubercular Therapy provides an up-to-date and thorough overview of the state-of-the-art of concepts, design, and recent advances in nanomedicines and nanobiotechnology-based strategies for the treatment of tuberculosis. The book enables researchers to prepare a variety of nanotechnology-based strategies, investigate their properties, and discover their uses and applications in antitubercular therapy, focusing on advanced nanomaterials that are utilized for encapsulation of nucleic acid, mRNA, DNA, and tuberculosis vaccination.This book covers all major topics that have shaped the development of nanomedicine and propelled it to its current place at the forefront of Nanotechnology based treatment innovation. It will be a welcomed resource for researchers and readers with more and more challenging therapy and biologicals with their possible modifications to be used for the effective therapy of tuberculosis.

This book explores the potential role of prebiotics, probiotics, and synbiotics in managing various metabolic disorders, chronic diseases, and metabolic syndromes. The initial chapter provides an overview of metabolic disorders, including their classification, symptoms, and underlying causes. Additionally, the chapter discusses the intricate signaling pathways and mechanisms through which prebiotics, probiotics, and synbiotics interact with the human body in relation to type-2 diabetes, obesity, Phenylketonuria, and Hemochromatosis. Additionally, the book highlights the potential impact of probiotics and synbiotics on oxidative stress, inflammation, lipid metabolism, and blood pressure. Furthermore, this book focuses on the gut-brain axis and how synbiotics may influence neurotransmitter metabolism. With an emphasis on the gut-microbiota axis, this book presents a compelling narrative that explores the rationality behind synbiotic use and offers a glimpse into future perspectives for managing metabolic disorders effectively. This book is intended for researchers in the fields of nutraceuticals, nanomedicine, endocrinology, nutrition, gastroenterology, and metabolic medicine who are working in the field of probiotics, prebiotics, and symbiotics for the treatment of metabolic disorders.

This book explores the potential role of prebiotics, probiotics, and synbiotics in managing various metabolic disorders, chronic diseases, and metabolic syndromes. The initial chapter provides an overview of metabolic disorders, including their classification, symptoms, and underlying causes. Additionally, the chapter discusses the intricate signaling pathways and mechanisms through which prebiotics, probiotics, and synbiotics interact with the human body in relation to type-2 diabetes, obesity, Phenylketonuria, and Hemochromatosis. Additionally, the book highlights the potential impact of probiotics and synbiotics on oxidative stress, inflammation, lipid metabolism, and blood pressure. Furthermore, this book focuses on the gut-brain axis and how synbiotics may influence neurotransmitter metabolism. With an emphasis on the gut-microbiota axis, this book presents a compelling narrative that explores the rationality behind synbiotic use and offers a glimpse into future perspectives for managing metabolic disorders effectively. This book is intended for researchers in the fields of nutraceuticals, nanomedicine, endocrinology, nutrition, gastroenterology, and metabolic medicine who are working in the field of probiotics, prebiotics, and symbiotics for the treatment of metabolic disorders.

This new volume delves into the extensive new research on inflammatory bowel disease (IBD) and gut microbiota that has led to effective therapeutic interventions. Highlighting novel methodologies and innovative treatment approaches, the book provides a comprehensive investigation of IBD, exploring the significance of gut microbiota and investigating the fundamental role of microbial imbalances in the initiation and progression of inflammatory processes as well as the prominent therapeutic consequences of restoring microbial homeostasis. From nanoparticle-based drug delivery systems that advance the bioavailability of the medicament to the use of bio-nanosensors for early detection of disease, the book covers a broad spectrum of inventions that hold potential for revolutionizing IBD treatment. The authors look at the impact of nutraceuticals, probiotics, prebiotics, functional foods, oral siRNA-based nanomedicine, and other novel drug delivery systems on gut microbiota for the management of IBD. The book also explores the role of reactive oxygen species (ROSs), superoxide dismutases (SODs), and inflammation in association with gut microbiota and IBD.

This new volume delves into the extensive new research on inflammatory bowel disease (IBD) and gut microbiota that has led to effective therapeutic interventions. Highlighting novel methodologies and innovative treatment approaches, the book provides a comprehensive investigation of IBD, exploring the significance of gut microbiota and investigating the fundamental role of microbial imbalances in the initiation and progression of inflammatory processes as well as the prominent therapeutic consequences of restoring microbial homeostasis. From nanoparticle-based drug delivery systems that advance the bioavailability of the medicament to the use of bio-nanosensors for early detection of disease, the book covers a broad spectrum of inventions that hold potential for revolutionizing IBD treatment. The authors look at the impact of nutraceuticals, probiotics, prebiotics, functional foods, oral siRNA-based nanomedicine, and other novel drug delivery systems on gut microbiota for the management of IBD. The book also explores the role of reactive oxygen species (ROSs), superoxide dismutases (SODs), and inflammation in association with gut microbiota and IBD.